E-submission
THE KOREAN LIVER CANCER ASSOCIATION
Search
- Page Path
- HOME > Search
Review Article
- Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment
- Bo Hyun Kim, Joong-Won Park
- J Liver Cancer. 2021;21(2):124-138. Published online September 30, 2021
- DOI: https://doi.org/10.17998/jlc.2021.09.23
- 3,951 Views
- 112 Downloads
- 2 Citations
-
Abstract
PDF - Several molecular-targeted agents have been tested as first- or second-line therapies for hepatocellular carcinoma (HCC) but failed to improve clinical outcomes; sorafenib has been the only approved systemic agent for treating HCC for almost 10 years. Regorafenib resulted in a significant improvement in overall survival and thus was approved for HCC patients previously treated with sorafenib. Subsequently, cabozantinib and ramucirumab demonstrated superior overall survival compared with placebos in phase III clinical trials. Immune checkpoint inhibitors such as nivolumab with or without ipilimumab and pembrolizumab are also available in some countries for patients who are unresponsive to sorafenib. Some second-line agents are available for patients who are unresponsive to sorafenib; however, little is known about the considerations for selecting appropriate secondline systemic agents. Hence, this study aimed to review the current and future perspectives of second-line systemic agents.
-
Citations
Citations to this article as recorded by
- Expression of Peptidyl Arginine Deiminase 2 Is Closely Associated with Recurrence in Patients with Hepatocellular Carcinoma
Sunho Uhm, Yoon Ah Cho, Ji-Young Choe, Ji Won Park, Min-Jeong Kim, Won-Ho Han, Junyong Lee, Jung Woo Lee, Dong Woo Shin, Jae Seung Soh, Hyun Lim, Ho Suk Kang, Sung-Hoon Moon, Sung-Eun Kim
Diagnostics.2023; 13(4): 659. CrossRef - Expert consensus on the management of adverse events in patients receiving lenvatinib for hepatocellular carcinoma
Bo Hyun Kim, Su Jong Yu, Wonseok Kang, Sung Bum Cho, Soo Young Park, Seung Up Kim, Do Young Kim
Journal of Gastroenterology and Hepatology.2022; 37(3): 428. CrossRef
- Expression of Peptidyl Arginine Deiminase 2 Is Closely Associated with Recurrence in Patients with Hepatocellular Carcinoma
First
Prev
Follow JLC on Twitter